In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
Puma Biotechnology Inc (NASDAQ: PBYI) closed the day trading at $3.02 up 2.37% from the previous closing price of $2.95. In other words, the price has increased by $2.37 from its previous closing price. On the day, 0.59 million shares were traded. PBYI stock price reached its highest trading level at $3.06 during the session, while it also had its lowest trading level at $2.915.
Ratios:
For a better understanding of PBYI, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.53 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 4.40. For the most recent quarter (mrq), Quick Ratio is recorded 1.40 and its Current Ratio is at 1.42. In the meantime, Its Debt-to-Equity ratio is 1.21 whereas as Long-Term Debt/Eq ratio is at 0.50.
Goldman Downgraded its Neutral to Sell on October 08, 2019, whereas the target price for the stock was revised from $24 to $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 02 ’25 when NOUGUES MAXIMO F sold 10,227 shares for $3.15 per share. The transaction valued at 32,232 led to the insider holds 152,295 shares of the business.
Ludwig Jeffrey Jerome sold 9,437 shares of PBYI for $29,743 on Jan 02 ’25. The Chief Commercial Officer now owns 108,951 shares after completing the transaction at $3.15 per share. On Jan 02 ’25, another insider, HUNT DOUGLAS M, who serves as the insider of the company, sold 8,633 shares for $3.15 each. As a result, the insider received 27,209 and left with 124,594 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PBYI now has a Market Capitalization of 148244848 and an Enterprise Value of 137889808. As of this moment, Puma’s Price-to-Earnings (P/E) ratio for their current fiscal year is 6.36, and their Forward P/E ratio for the next fiscal year is 8.88. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.61 while its Price-to-Book (P/B) ratio in mrq is 2.08. Its current Enterprise Value per Revenue stands at 0.566 whereas that against EBITDA is 3.092.
Stock Price History:
The Beta on a monthly basis for PBYI is 1.08, which has changed by -0.3942505 over the last 52 weeks, in comparison to a change of 0.24440956 over the same period for the S&P500. Over the past 52 weeks, PBYI has reached a high of $7.73, while it has fallen to a 52-week low of $2.22. The 50-Day Moving Average of the stock is -0.74%, while the 200-Day Moving Average is calculated to be -10.36%.
Shares Statistics:
Over the past 3-months, PBYI traded about 598.08K shares per day on average, while over the past 10 days, PBYI traded about 774550 shares per day. A total of 49.07M shares are outstanding, with a floating share count of 34.92M. Insiders hold about 28.86% of the company’s shares, while institutions hold 54.36% stake in the company. Shares short for PBYI as of 1735603200 were 3009262 with a Short Ratio of 5.03, compared to 1732838400 on 2805904. Therefore, it implies a Short% of Shares Outstanding of 3009262 and a Short% of Float of 7.22.
Earnings Estimates
The dynamic stock of Puma Biotechnology Inc (PBYI) is currently attracting attention from 2.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $0.06, with high estimates of $0.06 and low estimates of $0.06.
Analysts are recommending an EPS of between $0.51 and $0.49 for the fiscal current year, implying an average EPS of $0.5. EPS for the following year is $0.6, with 2.0 analysts recommending between $0.74 and $0.45.
Revenue Estimates
2 analysts predict $52.5M in revenue for the current quarter. It ranges from a high estimate of $53.2M to a low estimate of $51.8M. As of the current estimate, Puma Biotechnology Inc’s year-ago sales were $72.2MFor the next quarter, 2 analysts are estimating revenue of $47.5M. There is a high estimate of $47.5M for the next quarter, whereas the lowest estimate is $47.5M.
A total of 2 analysts have provided revenue estimates for PBYI’s current fiscal year. The highest revenue estimate was $224.6M, while the lowest revenue estimate was $223.2M, resulting in an average revenue estimate of $223.9M. In the same quarter a year ago, actual revenue was $235.6MBased on 2 analysts’ estimates, the company’s revenue will be $221.35M in the next fiscal year. The high estimate is $232.7M and the low estimate is $210M.
